Sponsored

Radiopharm (ASX:RAD) announces filing of application for Nasdaq listing, shares jump - Kalkine Media

February 14, 2023 07:09 PM AEDT | By Ankit Sethi
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • ASX-listed radiopharmaceuticals company RAD has filed a listing application and Form 20-F, to enter the Nasdaq stock exchange
  • Nasdaq listing would complement the company’s existing ASX listing
  • RAD says no capital would be raised, and its American Depositary Shares would be traded under the ticker RADX

ASX-listed Radiopharm Theranostics (ASX:RAD) has begun the process for listing of its American Depositary Shares on Nasdaq. The company -- which develops radiopharmaceutical products for diagnostic and therapeutic applications -- has said it has filed the listing application with the exchange and the requisite Form 20-F with the US Securities and Exchange Commission (SEC).

Below are more details related to the latest company development.

The proposed listing on Nasdaq

RAD has stated that Nasdaq and the SEC are expected to complete the review of respective filings of the company by end of March 2023. Post this, the listing of Radiopharm’s American Depositary Shares (ADS) is planned to occur.

Radiopharm has further informed that the company’s Nasdaq listing would be as a Level 2 American Depositary Receipt program. Here, a single ADS would represent 100 ordinary shares of RAD. Radiopharm would appoint Deutsche Bank Trust Company Americas in the capacity of depositary, custodian, and registrar for this new listing.

RAD’s already listed shares on ASX would continue to trade in the same manner as they do now after the Nasdaq listing. The company asserts that the development is a part of its strategy to expand Radiopharm’s reach to institutional and retail investors in the US. A Nasdaq listing would pave the way for purchase of RAD shares through the US equity market, with trading during the US time zone and in USD.

Shares gain

Triggered by the update, RAD shares gained more than 7.6% to trade at AU$0.140 in the early hours of 14 February 2023. 

To know about the quarterly developments of Radiopharm, read here  


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

5 ASX Companies Leveraging AI to Drive Growth in 2024



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.